The fundraising was co-led by Radical Ventures, which specialises in AI software companies, and European healthcare venture firm Sofinnova Partners. Other investors include Jeff Dean, Google’s chief ...

Drug discovery is a costly and time-intensive process, with binding free energy calculations between the potential drug ...

A novel geometric deep learning framework designs ligand-specific protein binders, enhancing therapeutic potential in cell therapies and synthetic biology.

His team harnesses advanced computational technologies, including AI, with the aim of enhancing the discovery, design, optimization and synthesis of small molecules to be developed into innovative ...

Innovative designs of GPCRs with enhanced signaling and stability offer new insights for drug discovery and synthetic biology ...

Researchers have developed a computational method to explicitly consider the impact of water while designing membrane receptors with enhanced stability and signaling, paving the way for novel drug ...

Bind Research launched to transform disordered proteins into effective drug targetsUK’s first not-for-profit Focused Research Organisation ...

Scientific Computing World is hosting a virtual roundtable in February for research leaders, scientists and R&D experts in drug discovery, particularly those working with new modalities, such as RNA ...

The partnership seeks to address challenges in small molecule screening and design of drugs by integrating AI ... Psivant ...

Dr Alan D. Roth, CEO of Oxford Drug Design, highlighted the significance of their achievement. “This new milestone is a testament to the accuracy and reliability of our computational platform, SynthAI ...

Dr. Alan D. Roth, CEO of Oxford Drug Design, added: “This new milestone for Oxford Drug Design is a testament not only to the accuracy and reliability of our computational platform, SynthAI, but also ...